Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 12, 2014, Pages

  Nagata, Takumi ^a   Suzuki, Masayuki ^a   Fukazawa, Masanori ^a   Honda, Kiyofumi ^a   Yamane, Mizuki ^a   Yoshida, Ayae ^b   Azabu, Hiroko ^b   Kitamura, Hidekazu ^b   Toyota, Naoto ^b   Suzuki, Yoshiyuki ^a   Kawabe, Yoshiki ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b Chugai Research Institute for Medical Science Inc   (Japan)

Author keywords

Sodium glucose transporter inhibitor; Splay; Transport maximum for glucose

Indexed keywords

PHLORIZIN; SODIUM GLUCOSE COTRANSPORTER 2; TOFOGLIFLOZIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; GLUCOSE URINE LEVEL; GLUCOSURIA; IN VITRO STUDY; IN VIVO STUDY; MACACA FASCICULARIS; MALE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; URINARY EXCRETION;

SODIUM-GLUCOSE TRANSPORTER INHIBITOR; SPLAY; TRANSPORT MAXIMUM FOR GLUCOSE;

ANIMALS; BENZHYDRYL COMPOUNDS; CERCOPITHECUS AETHIOPS; COS CELLS; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; GLUCOSIDES; KIDNEY; MACACA FASCICULARIS; MALE; METHYLGLUCOSIDES; MODELS, ANIMAL; PHLORHIZIN; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84902665809     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00076.2014     Document Type: Article

References (42)

1. Brodehl J, Oemar BS, Hoyer PF. Renal glucosuria. Pediatr Nephrol 1: 502-508, 1987.
2. Calado J, Santer R, Rueff J. Effect of kidney disease on glucose handling (including genetic defects). Kidney Int Suppl S7-S13, 2011.
3. Chao EC, Henry RR. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov 9: 551-559, 2010.
4. Chen H, Dardik B, Qiu L, Ren X, Caplan SL, Burkey B, Boettcher BR, Gromada J. Cevoglitazar, a novel peroxisome proliferator-activated receptor-alpha/gamma dual agonist, potently reduces food intake and body weight in obese mice and cynomolgus monkeys. Endocrinology 151: 3115-3124, 2010.
5. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 14: 5-14, 2012.
6. DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M, Morrow LA, Leslie BR, Boulton DW, Ching A, LaCreta FP, Griffen SC. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36: 3169-3176, 2013.
7. Dobbins RL, O'Connor-Semmes R, Kapur A, Kapitza C, Golor G, Mikoshiba I, Tao W, Hussey EK. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab 14: 15-22, 2012.
8. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8: 495-502, 2012.
9. Ferrannini E, Veltkamp SA, Smulders RA, Kadokura T. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 36: 1260-1265, 2013.
10. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57: 1723-1729, 2008.
11. Hummel CS, Lu C, Liu J, Ghezzi C, Hirayama BA, Loo DD, Kepe V, Barrio JR, Wright EM. Structural selectivity of human SGLT inhibitors. Am J Physiol Cell Physiol 302: C373-C382, 2012.
12. +/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 300: C14-C21, 2011.
13. Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL, Zhao X, Moeckel GW, Samuel VT, Whaley JM, Shulman GI, Kibbey RG. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60: 890-898, 2011.
14. +/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93: 397-404, 1994.
15. Kasichayanula S, Chang M, Hasegawa M, Liu X, Yamahira N, LaCreta FP, Imai Y, Boulton DW. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab 13: 357-365, 2011.
16. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 320: 323-330, 2007.
17. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148: 774-781, 2007.
18. Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, Du F, Liu Y, Xu J, Conway B, Conway J, Polidori D, Ways K, Demarest K. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 7: e30555, 2012.
19. Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 61: 2199-2204, 2012.
20. Lotspeich WD, Woronkow S. Some quantitative studies on phlorizin inhibition of glucose transport in the kidney. Am J Physiol 195: 331-336, 1958.
21. Martin L. Stochastic processes in physiology. In: Proceedings of the Berkeley Symposium on Mathematical Statistics and Probability. Oakland, CA: Univ. of California Press, 1961, p. 307.
22. McPhaul JJ Jr, Simonaitis JJ. Observations on the mechanisms of glucosuria during glucose loads in normal and nondiabetic subjects. J Clin Invest 47: 702-711, 1968.
23. Nagata T, Fukazawa M, Honda K, Yata T, Kawai M, Yamane M, Murao N, Yamaguchi K, Kato M, Mitsui T, Suzuki Y, Ikeda S, Kawabe Y. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo-or euglycemic conditions in rats. Am J Physiol Endocrinol Metab 304: E414-E423, 2013.
24. Ohtake Y, Sato T, Kobayashi T, Nishimoto M, Taka N, Takano K, Yamamoto K, Ohmori M, Yamaguchi M, Takami K, Yeu SY, Ahn KH, Matsuoka H, Morikawa K, Suzuki M, Hagita H, Ozawa K, Yamaguchi K, Kato M, Ikeda S. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 55: 7828-7840, 2012.
25. +/glucose cotransporters. J Pharmacol Exp Ther 324: 985-991, 2008.
26. Polidori D, Sha S, Ghosh A, Plum-Morschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 98: E867-E871, 2013.
27. Rieselbach RE, Shankel SW, Slatopolsky E, Lubowitz H, Bricker NS. Glucose titration studies in patients with chronic progressive renal disease. J Clin Invest 46: 157-163, 1967.
28. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5: 133-141, 2010.
29. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li Volti S, Neuhaus T, Skovby F, Swift PG, Schaub J, Klaerke D. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14: 2873-2882, 2003.
30. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13: 669-672, 2011.
31. Shankel SW, Robson AM, Bricker NS. On the mechanism of the splay in the glucose titration curve in advanced experimental renal disease in the rat. J Clin Invest 46: 164-172, 1967.
32. Suzuki M, Honda K, Fukazawa M, Ozawa K, Hagita H, Kawai T, Takeda M, Yata T, Kawai M, Fukuzawa T, Kobayashi T, Sato T, Kawabe Y, Ikeda S. Tofogliflozin, a potent and highly specific sodium/ glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 341: 692-701, 2012.
33. +-glucose cotransporter suppresses blood glucose elevation in dogs. Biol Pharm Bull 29: 114-118, 2006.
34. Usberti M, Andreucci VE. Relationship of glomerular filtration rate and hypoalbuminaemia to renal glucose reabsorption. Proc Eur Dial Transplant Assoc 12: 174-182, 1976.
35. Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 300: R1009-R1022, 2011.
36. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, Rieg T. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22: 104-112, 2011.
37. Wagner JD, Shadoan MK, Zhang L, Ward GM, Royer LJ, Kavanagh K, Francone OL, Auerbach BJ, Harwood HJ Jr. A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys. J Pharmacol Exp Ther 333: 844-853, 2010.
38. Weekley LB, Deldar A, Tapp E. Development of renal function tests for measurement of urine concentrating ability, urine acidification, and glomerular filtration rate in female cynomolgus monkeys. Contemp Top Lab Anim Sci 42: 22-25, 2003.
39. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 91: 733-794, 2011.
40. Yamaguchi K, Kato M, Suzuki M, Asanuma K, Aso Y, Ikeda S, Ishigai M. Pharmacokinetic and pharmacodynamic modeling of the effect of an sodium-glucose cotransporter inhibitor, phlorizin, on renal glucose transport in rats. Drug Metab Dispos 39: 1801-1807, 2011.
41. Yamamoto K, Uchida S, Kitano K, Fukuhara N, Okumura-Kitajima L, Gunji E, Kozakai A, Tomoike H, Kojima N, Asami J, Toyoda H, Arai M, Takahashi T, Takahashi K. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol 164: 181-191, 2011.
42. Zanardi TA, Han SC, Jeong EJ, Rime S, Yu RZ, Chakravarty K, Henry SP. Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2. J Pharmacol Exp Ther 343: 489-496, 2012.